Frazier Life Sciences

Frazier Life Sciences is the dedicated life sciences investment strategy of Frazier Healthcare Partners, a prominent private equity firm established in 1991. Based in Menlo Park, California, with an additional office in Seattle, Washington, the firm has a long-standing history of investing across the healthcare sector. Frazier Life Sciences specifically focuses on identifying, investing in, and building companies that are developing and commercializing novel therapeutics. Their investment philosophy often involves leading or co-leading financing rounds for early-stage and development-stage biopharmaceutical companies, providing significant capital and strategic guidance to help these ventures advance their pipelines.

The firm's commitment to the life sciences sector is underscored by its substantial capital raises. In 2022, Frazier Life Sciences successfully closed its eleventh fund, Frazier Life Sciences XI, with an impressive $830 million in committed capital. This followed the closure of Frazier Life Sciences X in 2019, which secured $675 million. These large fund sizes enable Frazier Life Sciences to make substantial initial investments and provide follow-on capital, supporting companies through various stages of clinical development and commercialization. Their portfolio typically comprises companies focused on a wide range of therapeutic areas, including oncology, immunology, rare diseases, and neuroscience.

Frazier Life Sciences is known for its hands-on approach, often working closely with management teams to build companies from inception or to scale existing businesses. Their typical first check sizes reflect their strategy of being a lead or significant investor in capital-intensive biopharmaceutical development. While specific initial check sizes can vary based on the stage and capital requirements of the company, Frazier Life Sciences generally commits between $15 million and $75 million for its initial investments. This substantial range allows them to back promising therapeutic platforms and drug candidates that require significant funding to reach key milestones, ultimately aiming to bring transformative medicines to patients.